opexibu.wordpress.com
Genzyme (NASDAQ: GENZ) found a virus strain and stopped production of two drugse atthe Allston, Mass., facility. The strain, Vesivirue 2117, apparently does not causwe human infection but interrupts the growth of cells that are used to make Aldurazyme — a treatment for MPS I, a rare and fata disease caused by an enzyme deficiency — was last filled at the Genzyme facilitu in September 2008, accordingf to BioMarin (NASDAQ: The company has about 10 monthsz of vialed inventory on hand, it said, and uses a secon fill finish supplier. A third suppliefr is expected to be qualified later this BioMarin said. BioMarin makes the bulk material used in Aldurazymed at itsNovato facility.
The Food and Drug Administratio hadinspected Genzyme’s plant in September and Octoberr and reportedly was concerned about controls to protec against contamination.
No comments:
Post a Comment